mepa8 Get alerts

FDA launches EAST program to test drugs bought from pharmacies and wholesalers

The agency says test results will guide regulatory action and inspection planning, and that samples flagged in screening will get confirmatory testing with validated methods.

Mepa8 headline card: FDA launches EAST program to test drugs bought from pharmacies and wholesalers

Key takeaways

  • The FDA announced the launch of its Enhanced Approach for Sampling and Testing (EAST) on November 18, 2026.
  • Under EAST, the agency buys drug samples commercially from retail pharmacies and wholesale distributors and tests them for identity, purity and potency.
  • The FDA says it will use the results to identify quality risks, decide whether regulatory action is needed and plan future inspections.
  • Samples referred for further evaluation get confirmatory testing with established, validated methods, and results are to be posted in the Results section of the FDA's Drug Quality Sampling and Testing Programs page.
  • For crews: the FDA records do not name the products, manufacturers or lots that EAST will sample, and they announce no recall or product action.

The Food and Drug Administration on Wednesday, November 18, 2026, announced the launch of its Enhanced Approach for Sampling and Testing, or EAST, a program that tests drug samples taken from retail pharmacies and wholesale distributors, according to an agency announcement dated the same day [1].

The FDA said EAST pairs modern screening techniques with traditional testing methods so the agency can test more drugs and find possible quality problems sooner [1]. The announcement said the initiative widens testing to more manufacturers, therapeutic classes and geographic regions, inside the United States and abroad [1].

"The EAST initiative gives us an enhanced way to monitor drug quality across an increasingly complex global supply chain," Dr. Michael Kopcha, director of the FDA's Office of Pharmaceutical Quality, said in the announcement [1].

What the records show

The FDA's program page says samples are bought commercially, with the aim of reaching the products patients and consumers actually use [2]. The agency picks products to represent a broad range of manufacturers, therapeutic classes and regions, and the page says that includes drugs made domestically and internationally [2].

The primary evaluations cover what the program page calls critical quality attributes [2]:

  • Identity: whether the correct active pharmaceutical ingredient is present.
  • Purity: an evaluation of impurities.
  • Potency: a check of the amount of active ingredient.

The page says more tests may be run when there are specific concerns about a product attribute [2]. Samples referred for further evaluation go on to confirmatory testing with established, validated analytical methods, such as those described in the United States Pharmacopeia [2].

The FDA said it will use the results to identify potential quality risks, decide whether regulatory action is needed and plan future inspections [1]. The program page adds that the data are meant to inform risk-based assessment and regulatory policy [2].

The agency describes the goal as broader surveillance coverage "within the same resource constraints," according to the program page, without lowering the analytical and evidentiary standards used for regulatory decisions [2]. The page also says the approach is intended to increase direct evaluation of products from global manufacturers without disrupting the availability of medicines [2].

Why it matters for clinicians

EAST samples drugs at the point where they are sold and distributed, rather than only at the border or at the factory. The program page says purchases come from retail pharmacies and wholesale distributors [2]. The records do not say whether the wholesale channels sampled include those that supply hospitals, ambulance services or other clinical settings.

The FDA's existing results table shows the kinds of products its surveillance testing already covers. Entries in the portion of the table reviewed include atropine sulfate solution, amlodipine besylate tablets, amoxicillin tablets, extended-release metformin hydrochloride tablets and atorvastatin calcium tablets [3]. Most of those entries carry the result "Passed Tests" [3].

The FDA says that when a product has unfavorable results, its Center for Drug Evaluation and Research shares information with health care professionals and consumers and alerts the manufacturer that it needs to correct the underlying problem [3]. The center then continues monitoring until the manufacturer demonstrates compliance, according to the agency [3].

Context

The announcement says EAST builds on testing the FDA already does [1]. The agency's sampling and testing page says its drug center runs a quality surveillance program that tests selected drugs, including active pharmaceutical ingredients, in FDA laboratories, generally to U.S. Pharmacopeia standards [3]. Attributes listed there are identity, assay, impurities and dissolution [3].

That page says the FDA uses a risk-based approach and that, starting in 2018, the center began using data analytics, including post-market quality data, to pick out products with potential quality risks [3]. The agency says the targeted approach has helped it find more failing products per year than in the years before 2018 [3]. It also states that "the majority of drugs FDA tests meet their specifications" [3].

Failures do appear in the table. An entry for atorvastatin calcium tablets from Alkem Laboratories Limited, tested under import surveillance, reads "Dissolution Failed Test; Assay, Impurities and Micro Non Sterile Passed" [3]. The entries reviewed list the reason for testing as either import surveillance or annual surveillance sampling and testing [3].

What the records do not tell us

  • The records do not say how many samples the FDA plans to buy or test under EAST, or over what period.
  • No products, manufacturers, lots or therapeutic classes are named as EAST targets.
  • The records do not identify the specific screening techniques described as modern or rapid.
  • The criteria for referring a sample to confirmatory testing are not described.
  • The records give no schedule for posting EAST results, and they do not say whether any entry in the current results table came from EAST.
  • No recall, warning or other regulatory action is tied to EAST in the records.
  • The records do not state a budget or staffing level for the program.

What to watch

The program page says EAST results will be reported in the "Results" section of the FDA's Drug Quality Sampling and Testing Programs page [2]. The records give no date for the first posting.

Questions readers ask

What is the FDA's EAST initiative?

EAST stands for Enhanced Approach for Sampling and Testing. The FDA announced its launch on November 18, 2026, describing it as a program that combines modern screening techniques with traditional testing methods to test more drugs and identify potential quality issues faster.

Where does the FDA get the drug samples it tests under EAST?

According to the FDA program page, samples are purchased commercially from retail pharmacies and wholesale distributors. The agency says it selects products for broad representation across manufacturers, therapeutic classes and geographic regions, including domestic and internationally manufactured drugs.

What does the FDA test for in the EAST program?

The primary evaluations focus on identity, purity and potency, according to the FDA. The agency says additional tests may be performed if there are specific concerns, and samples referred for further evaluation get confirmatory testing with established, validated analytical methods.

Where will FDA publish EAST drug testing results?

The FDA program page says results will be reported under the Results section of the FDA Drug Quality Sampling and Testing Programs page. The records do not give a date for the first posting.

Sources

  1. FDA: FDA Introduces New Approach to Drug Quality Sampling and Testing (November 18, 2026) — fda.gov (2026-11-18). fda.gov/drugs/drug-alerts-and-statements/fda-introduces-new-approach-d
  2. FDA: FDA's Enhanced Approach for Sampling and Testing (program page) — fda.gov (2026-11-18). fda.gov/drugs/science-and-research-drugs/fdas-enhanced-approach-sampli
  3. FDA: Drug Quality Sampling and Testing Programs (background and results table) — fda.gov (2026-11-18). fda.gov/drugs/science-and-research-drugs/drug-quality-sampling-and-tes
How this story was made Drafted by Mepa8's AI newsroom from the 3 records listed above and nothing else. Before publication a verification program confirmed that every number and quotation in the story appears in those records, that no passage was copied from them, and that every cited link opens. Editor: Ryan Bolden, EMS professional, who reviews published stories and handles corrections. Medical review pending. How we use AI · Report an error

This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.

Free alerts

Know about the next recall or outbreak the day it is posted.

One email when a story touches EMS equipment, medications or public health. Plus the free 6am briefing if you want it.

Send me